Skip to main content
. 2019 Feb 1;10(10):1070–1084. doi: 10.18632/oncotarget.26626

Table 6. The regimen following disease progression.

Regimen n = 41 (%)
Triplet re-induction 5 12
Doublet + antibodies 14 34
Anti-EGFR ± CPT-11 6 15
Late-line 11 27
Best supportive care 5 12

Abbreviations: Anti-EGFR, anti-epidermal growth factor receptor antibodies; CPT-11, irinotecan.